Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Cell

Volumn 162, Issue 6, 2015, Pages 1271-1285

  Hugo, Willy ^a,b   Shi, Hubing ^a,b   Sun, Lu ^a,b   Piva, Marco ^a,b   Song, Chunying ^a,b   Kong, Xiangju ^a,b   Moriceau, Gatien ^a,b   Hong, Aayoung ^a,b   Dahlman, Kimberly B ^d   Johnson, Douglas B ^d   Sosman, Jeffrey A ^d   Ribas, Antoni ^b,c   Lo, Roger S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; DIMETHYL SULFOXIDE; GENOMIC DNA; LYMPHOID ENHANCER FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SCH 772984; SELUMETINIB; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG; VEMURAFENIB; BETA CATENIN; LEF1 PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN TYROSINE KINASE; RON PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANTIGEN PRESENTATION; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MELANOMA; MOLECULAR EVOLUTION; PRIORITY JOURNAL; TRANSCRIPTOMICS; TUMOR BIOPSY; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION; APOPTOSIS; DNA METHYLATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; BETA CATENIN; CD8-POSITIVE T-LYMPHOCYTES; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; LYMPHOID ENHANCER-BINDING FACTOR 1; MAP KINASE SIGNALING SYSTEM; MELANOMA; PHOSPHOPROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84941350733     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2015.07.061     Document Type: Article

References (32)

1. T.L. Biechele, R.M. Kulikauskas, R.A. Toroni, O.M. Lucero, R.D. Swift, R.G. James, N.C. Robin, D.W. Dawson, R.T. Moon, and A.J. Chien Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma Sci. Signal. 5 2012 ra3
2. L. Ferrari de Andrade, S.F. Ngiow, K. Stannard, S. Rusakiewicz, M. Kalimutho, K.K. Khanna, S.K. Tey, K. Takeda, L. Zitvogel, L. Martinet, and M.J. Smyth Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma Cancer Res. 74 2014 7298 7308
3. M.R. Girotti, M. Pedersen, B. Sanchez-Laorden, A. Viros, S. Turajlic, D. Niculescu-Duvaz, A. Zambon, J. Sinclair, A. Hayes, M. Gore, and et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma Cancer Discov. 3 2013 158 167
4. + tumor-reactive repertoire infiltrating human tumors J. Clin. Invest. 124 2014 2246 2259
5. C.M. Johannessen, J.S. Boehm, S.Y. Kim, S.R. Thomas, L. Wardwell, L.A. Johnson, C.M. Emery, N. Stransky, A.P. Cogdill, J. Barretina, and et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 2010 968 972
6. C.M. Johannessen, L.A. Johnson, F. Piccioni, A. Townes, D.T. Frederick, M.K. Donahue, R. Narayan, K.T. Flaherty, J.A. Wargo, D.E. Root, and L.A. Garraway A melanocyte lineage program confers resistance to MAP kinase pathway inhibition Nature 504 2013 138 142
7. D.A. Knight, S.F. Ngiow, M. Li, T. Parmenter, S. Mok, A. Cass, N.M. Haynes, K. Kinross, H. Yagita, R.C. Koya, and et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors J. Clin. Invest. 123 2013 1371 1381
8. J. Larkin, P.A. Ascierto, B. Dréno, V. Atkinson, G. Liszkay, M. Maio, M. Mandalà, L. Demidov, D. Stroyakovskiy, L. Thomas, and et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma N. Engl. J. Med. 371 2014 1867 1876
9. S. Laurent, P. Queirolo, S. Boero, S. Salvi, P. Piccioli, S. Boccardo, S. Minghelli, A. Morabito, V. Fontana, G. Pietra, and et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production J. Transl. Med. 11 2013 108
10. M. Lidsky, G. Antoun, P. Speicher, B. Adams, R. Turley, C. Augustine, D. Tyler, and F. Ali-Osman Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells J. Biol. Chem. 289 2014 27714 27726
11. G.V. Long, C. Fung, A.M. Menzies, G.M. Pupo, M.S. Carlino, J. Hyman, H. Shahheydari, V. Tembe, J.F. Thompson, R.P. Saw, and et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma Nat. Commun. 5 2014 5694
12. G.V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, J.J. Grob, and et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma N. Engl. J. Med. 371 2014 1877 1888
13. S. Mok, J. Tsoi, R.C. Koya, S. Hu-Lieskovan, B.L. West, G. Bollag, T.G. Graeber, and A. Ribas Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition BMC Cancer 15 2015 356
14. G. Moriceau, W. Hugo, A. Hong, H. Shi, X. Kong, C.C. Yu, R.C. Koya, A.A. Samatar, N. Khanlou, J. Braun, and et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction Cancer Cell 27 2015 240 256
15. J. Müller, O. Krijgsman, J. Tsoi, L. Robert, W. Hugo, C. Song, X. Kong, P.A. Possik, P.D. Cornelissen-Steijger, M.H. Foppen, and et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma Nat. Commun. 5 2014 5712
16. R. Nazarian, H. Shi, Q. Wang, X. Kong, R.C. Koya, H. Lee, Z. Chen, M.K. Lee, N. Attar, H. Sazegar, and et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 2010 973 977
17. A.C. Obenauf, Y. Zou, A.L. Ji, S. Vanharanta, W. Shu, H. Shi, X. Kong, M.C. Bosenberg, T. Wiesner, N. Rosen, and et al. Therapy-induced tumour secretomes promote resistance and tumour progression Nature 520 2015 368 372
18. K.H. Paraiso, M. Das Thakur, B. Fang, J.M. Koomen, I.V. Fedorenko, J.K. John, H. Tsao, K.T. Flaherty, V.K. Sondak, J.L. Messina, and et al. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype Cancer Discov. 5 2015 264 273
19. H. Rizos, A.M. Menzies, G.M. Pupo, M.S. Carlino, C. Fung, J. Hyman, L.E. Haydu, B. Mijatov, T.M. Becker, S.C. Boyd, and et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact Clin. Cancer Res. 20 2014 1965 1977
20. M.S. Rooney, S.A. Shukla, C.J. Wu, G. Getz, and N. Hacohen Molecular and genetic properties of tumors associated with local immune cytolytic activity Cell 160 2015 48 61
21. B. Sanchez-Laorden, A. Viros, M.R. Girotti, M. Pedersen, G. Saturno, A. Zambon, D. Niculescu-Duvaz, S. Turajlic, A. Hayes, M. Gore, and et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling Sci. Signal. 7 2014 ra30
22. H. Shi, X. Kong, A. Ribas, and R.S. Lo Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition Cancer Res. 71 2011 5067 5074
23. H. Shi, G. Moriceau, X. Kong, R.C. Koya, R. Nazarian, G.M. Pupo, A. Bacchiocchi, K.B. Dahlman, B. Chmielowski, J.A. Sosman, and et al. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors Cancer Discov. 2 2012 414 424
24. H. Shi, G. Moriceau, X. Kong, M.K. Lee, H. Lee, R.C. Koya, C. Ng, T. Chodon, R.A. Scolyer, K.B. Dahlman, and et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance Nat. Commun. 3 2012 724
25. H. Shi, A. Hong, X. Kong, R.C. Koya, C. Song, G. Moriceau, W. Hugo, C.C. Yu, C. Ng, T. Chodon, and et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition Cancer Discov. 4 2014 69 79
26. H. Shi, W. Hugo, X. Kong, A. Hong, R.C. Koya, G. Moriceau, T. Chodon, R. Guo, D.B. Johnson, K.B. Dahlman, and et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy Cancer Discov. 4 2014 80 93
27. R. Straussman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z.R. Qian, J. Du, A. Davis, M.M. Mongare, J. Gould, D.T. Frederick, and et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 487 2012 500 504
28. C. Twyman-Saint Victor, A.J. Rech, A. Maity, R. Rengan, K.E. Pauken, E. Stelekati, J.L. Benci, B. Xu, H. Dada, P.M. Odorizzi, and et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer Nature 520 2015 373 377
29. E.M. Van Allen, N. Wagle, A. Sucker, D.J. Treacy, C.M. Johannessen, E.M. Goetz, C.S. Place, A. Taylor-Weiner, S. Whittaker, G.V. Kryukov, et al. Dermatologic Cooperative Oncology Group of Germany (DeCOG) The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma Cancer Discov. 4 2014 94 109
30. J. Villanueva, J.R. Infante, C. Krepler, P. Reyes-Uribe, M. Samanta, H.Y. Chen, B. Li, R.K. Swoboda, M. Wilson, A. Vultur, and et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma Cell Rep. 4 2013 1090 1099
31. N. Wagle, C. Emery, M.F. Berger, M.J. Davis, A. Sawyer, P. Pochanard, S.M. Kehoe, C.M. Johannessen, L.E. Macconaill, W.C. Hahn, and et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling J. Clin. Oncol. 29 2011 3085 3096
32. N. Wagle, E.M. Van Allen, D.J. Treacy, D.T. Frederick, Z.A. Cooper, A. Taylor-Weiner, M. Rosenberg, E.M. Goetz, R.J. Sullivan, D.N. Farlow, and et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition Cancer Discov. 4 2014 61 68